Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Danaher (NYSE: DHR) reported third quarter 2025 results for the period ended September 26, 2025. Revenue rose 4.5% YoY to $6.1B and non-GAAP core revenue increased 3.0% YoY. Net earnings were $908M, or $1.27 per diluted share; adjusted diluted EPS was $1.89. Operating cash flow was $1.7B and non-GAAP free cash flow was $1.4B. The company maintained full‑year 2025 adjusted diluted EPS guidance of $7.70–$7.80 and expects non‑GAAP core revenue to grow in the low‑single digits for 2025. Management highlighted bioprocessing momentum and stronger respiratory revenue at Cepheid. The company disclosed estimated 2025 acquisition amortization of $1.7B and an estimated +1.0% FX sales impact for the full year.
Danaher (NYSE:DHR) has scheduled its Q3 2025 earnings conference call for October 21, 2025 at 8:00 a.m. ET. The one-hour call will include discussions on financial performance and future outlook. The presentation will be accessible via webcast on Danaher's website under the "Investors" section.
Participants can join by dialing 800-245-3047 (U.S.) or +1 203-518-9765 (international). The earnings materials, including press release, slides, Form 10-Q, and non-GAAP reconciliations, will be available on the company's website at 6:00 a.m. ET on the call date. A replay will be available until November 4, 2025.
Beckman Coulter Diagnostics, a Danaher (NYSE:DHR) company, has launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. The test is available on the DxI 9000 Immunoassay Analyzer and Access 2 Analyzer platforms.
BD-Tau represents a significant advancement in neurodegenerative research, offering enhanced specificity compared to traditional tau markers. The test directly detects brain-derived tau in blood, providing a more precise indicator of neurodegeneration. Additionally, the company announced the development of an Aβ-42 RUO immunoassay test, marking progress toward their FDA Breakthrough Device Designation for a p-Tau 217/Aβ-42 ratio test.
Danaher Corporation (NYSE: DHR) has announced its Board of Directors approved a regular quarterly cash dividend of $0.32 per share of common stock. The dividend will be paid on October 31, 2025 to shareholders of record as of September 26, 2025.
Danaher (NYSE: DHR) has appointed Jonathan Leiken as Senior Vice President and General Counsel, effective August 25, 2025. Leiken, who brings nearly three decades of legal and leadership experience, will report to CEO Rainer Blair and join the Danaher Leadership Team.
Leiken succeeds Brian Ellis, who will retire after nearly 10 years as General Counsel. Ellis will remain with Danaher through February 2026 to support the transition. Prior to joining Danaher, Leiken served as Executive VP and Chief Legal Officer at Dollar Tree and Diebold Nixdorf, and has experience as a federal prosecutor and law firm partner.
Danaher (NYSE: DHR) announced that Matthew Gugino will succeed Matthew McGrew as Chief Financial Officer, effective February 28th, 2026. Gugino, currently Group CFO of Life Sciences Innovations Group and VP of Financial Planning & Analysis, brings extensive experience in Investor Relations, FP&A, and M&A.
McGrew, who has served as CFO since 2019, will transition to an Executive VP role as he approaches retirement after 20+ years with the company. During his CFO tenure, Danaher nearly doubled both revenue and market capitalization while improving growth and margin profiles. McGrew played key roles in the Cytiva acquisition and the launches of Envista and Veralto.
Danaher (NYSE: DHR) reported strong second quarter 2025 results, with revenues increasing 3.5% year-over-year to $5.9 billion and non-GAAP core revenue growth of 1.5%. The company posted net earnings of $555 million, or $0.77 per diluted share, while non-GAAP adjusted diluted earnings reached $1.80 per share.
Operating cash flow stood at $1.3 billion, with non-GAAP free cash flow of $1.1 billion. For full year 2025, Danaher maintains its core revenue growth forecast of approximately 3% and has raised its adjusted EPS guidance to $7.70-$7.80 from the previous $7.60-$7.75. The company expects low-single-digit core revenue growth for Q3 2025.
Danaher (NYSE:DHR) has appointed Martin Stumpe as Chief Technology and AI Officer, effective October 1, 2025. Reporting directly to CEO Rainer Blair, Dr. Stumpe will lead the company's digital transformation initiatives and AI integration across its global businesses.
Dr. Stumpe, who joined Danaher in 2024 as Chief Data and AI Officer, brings significant expertise from his previous roles at Tempus, where he led AI initiatives in precision medicine, and Google, where he founded the Cancer Pathology project. His appointment aims to accelerate scientific discovery, operational efficiency, and clinical impact in life sciences and diagnostics.
Danaher (NYSE:DHR) has appointed Greg Milosevich as Executive Vice President of its Life Sciences business, effective July 1, 2025. Milosevich, who has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021, will become an executive officer while continuing to report to CEO Rainer Blair.
Milosevich joined Danaher in 2010 through the Molecular Devices acquisition and has overseen multiple companies including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a physics degree from the University of Puget Sound.